Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Target Price of $290.00 According to Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $300.11.

A number of equities analysts recently commented on the company. Robert W. Baird increased their price objective on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Mizuho upped their price target on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a report on Friday, September 25th. TD Cowen upped their price target on Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a report on Friday, September 25th. Jefferies Financial Group raised their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. Finally, Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st.

Insider Activity

In related news, EVP Shannon M. Parisotto sold 5,046 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 90,990 shares of company stock valued at $25,731,388. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after purchasing an additional 9,756 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after purchasing an additional 54,500 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Charles River Laboratories International by 8.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company’s stock valued at $166,813,000 after buying an additional 66,803 shares in the last quarter. Finally, Amundi raised its holdings in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after buying an additional 492,301 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.6%

NYSE CRL opened at $305.95 on Wednesday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International has a 1-year low of $146.20 and a 1-year high of $333.30. The firm’s fifty day simple moving average is $280.49 and its 200-day simple moving average is $220.15. The company has a market capitalization of $14.61 billion, a PE ratio of -63.08, a price-to-earnings-growth ratio of 2.91 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter last year, the firm earned $3.12 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 11.36 earnings per share for the current fiscal year.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: New laboratory-technology partnership: Charles River and Autolomous announced a collaboration to improve laboratory execution systems. Their Apollo Orchestrate solution is designed to coordinate digital laboratory workflows within Charles River’s Apollo platform, potentially strengthening the company’s technology offering and creating longer-term growth opportunities. Charles River and Autolomous Partner to Transform Laboratory Execution Systems
• Positive Sentiment: Analysts modestly raised earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. Quarterly estimates for 2027 and 2028 were also raised slightly. The revisions indicate incremental confidence in Charles River’s earnings outlook, although the changes are relatively small and remain below the broader current-year consensus of $11.42. Research Analysts Offer Predictions for CRL FY2026 Earnings
• Neutral Sentiment: Recent momentum may be prompting consolidation: CRL recently gained 5.6% in a broad market rally and reached a new 52-week high. With the stock trading well above its 50-day and 200-day moving averages, investors may be locking in gains following the sharp advance. Charles River Laboratories International Jumps 5.6% in Broad Rally
• Negative Sentiment: Valuation and earnings risks remain: The stock’s rally has increased valuation sensitivity, while the company’s latest reported revenue declined 2.7% year over year and its net margin was negative. These factors could encourage profit-taking even as analysts maintain a generally positive earnings trajectory.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.